前列腺癌治疗模式的转变；多西他赛联合低剂量泼尼松——终于有了一种有效的化疗方法。

Shifting paradigms in prostate cancer; docetaxel plus low-dose prednisone - finally an effective chemotherapy.

作者信息

de Wit Ronald

机构信息

Rotterdam Cancer Institute, Erasmus University Medical Center, Department of Medical Oncology, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands.

出版信息

Eur J Cancer. 2005 Mar;41(4):502-7. doi: 10.1016/j.ejca.2004.12.007. Epub 2005 Jan 26.

DOI:10.1016/j.ejca.2004.12.007

PMID:15737553

Abstract

Until now, the use of systemic chemotherapy for advanced androgen-independent prostate cancer has had very little to offer to patients. However, in 2004, two large randomised trials investigating docetaxel vs. mitoxantrone have both demonstrated survival improvements, and, in one of the trails, improvements in important secondary clinical outcome measures such as pain relief and quality of life measurements. In this current perspective, these two trials are summarised and discussed. It is concluded that, docetaxel every 3 weeks plus low-dose prednisone can be considered standard treatment for patients with androgen-independent disease.

摘要

到目前为止，全身化疗用于晚期雄激素非依赖性前列腺癌对患者几乎没有什么作用。然而，在2004年，两项研究多西他赛与米托蒽醌对比的大型随机试验均证明了生存率的提高，并且在其中一项试验中，在重要的次要临床结局指标如疼痛缓解和生活质量测量方面也有改善。在本综述中，对这两项试验进行了总结和讨论。得出的结论是，每3周一次的多西他赛联合低剂量泼尼松可被视为雄激素非依赖性疾病患者的标准治疗方法。